Effect of the CCR5 antagonist maraviroc on circulating bacterial DNA level and on immune activation. Bacterial 16S ribosomal DNA plasma levels (A) and percentage of CD8⁺ T cells coexpressing HLA-DR and CD38 (B) in nonimmunologic responders to antiretroviral therapy to whom the CCR5 antagonist maraviroc was added for 6 months.